Haidian, Beijing, China The main office of represented VC is situated in the Haidian. The fund was located in Asia if to be more exact in China.
Among the various public portfolio startups of the fund, we may underline Ansun BioPharma, JW Therapeutics, CANbridge Life Sciences Among the most successful fund investment fields, there are Music, Health Care. The fund has exact preference in some founders of portfolio startups. For fund there is a match between the country of its foundation and the country of its the most frequent investments - China. Moreover, a startup needs to be at the age of 6-10 years to get the investment from the fund.
The standard case for the fund is to invest in rounds with 5-6 partakers. Despite the YuanMing Capital, startups are often financed by Venrock, CHL Medical Partners, ProQuest Investments. The meaningful sponsors for the fund in investment in the same round are Oriza Seed Capital (Oriza Yuandian), WuXi AppTec, Matrix Partners China. In the next rounds fund is usually obtained by State Development & Investment Corporation (SDIC), RMB Funds, Qiming Venture Partners.
The fund was created by Fiona Gong, Lawrence Tian, Ming Jiang, Tina Yu. We also calculated 3 valuable employees in our database.
The high activity for fund was in 2018. The top amount of exits for fund were in 2010. This YuanMing Capital works on 19 percentage points less the average amount of lead investments comparing to the other organizations. The average startup value when the investment from YuanMing Capital is 100-500 millions dollars. The usual things for fund are deals in the range of 50 - 100 millions dollars. The real fund results show that this VC is 20 percentage points more often commits exit comparing to other companies. The fund is constantly included in less than 2 deals per year.
Related Funds
Funds with similar focus
| Fund Name | Location |
| Boquan Capital | China, Hongkou District |
| Bull City Venture Partners | North Carolina, Raleigh, United States |
| CITIC Industrial Investment Group | - |
| Dawn Patrol Ventures | California, Santa Monica, United States |
| DonBest | California, Los Angeles, United States |
| Jishi Ronghui | China, Futian, Guangdong |
| Mahindra finance | India, Maharashtra, Mumbai |
| Necotium | Barcelona, Catalonia, Spain |
| Pacific Venture Capital | - |
| reinmkr capital | California, Marina Del Rey, United States |
| Shi Shi Management | Beijing, China, Fengtai |
| SME Support JAPAN | - |
| Syntek Capital | Bavaria, Bayern, Germany |
| TriTech Software Systems | California, San Diego, United States |
| US Invest | Arizona, Tempe, United States |
| ZZ Capital | Beijing, Beijing, China |
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
Ascentage Pharma | $150M | 17 Jul 2018 | Jiangsu | ||
Adlai Nortye | $53M | 26 Jun 2018 | Shangcheng District, Zhejiang, China | ||
Ansun BioPharma | $85M | 14 May 2018 | San Diego, California, United States | ||
JW Therapeutics | $90M | 07 Mar 2018 | Shanghai, China | ||
CANbridge Pharmaceuticals | $25M | 23 May 2017 | China, Beijing | ||
Ascentage Pharma | $77M | 26 Dec 2016 | China, Gusu District | ||
aptX | $20M | 28 Jan 2016 | Belfast, Northern Ireland, United Kingdom | ||
Ascentage Pharma | $15M | 14 Aug 2015 | Jiangsu |
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
Ascentage Pharma | $150M | 17 Jul 2018 | Jiangsu | ||
Adlai Nortye | $53M | 26 Jun 2018 | Shangcheng District, Zhejiang, China | ||
Ansun BioPharma | $85M | 14 May 2018 | San Diego, California, United States | ||
JW Therapeutics | $90M | 07 Mar 2018 | Shanghai, China | ||
CANbridge Pharmaceuticals | $25M | 23 May 2017 | China, Beijing | ||
Ascentage Pharma | $77M | 26 Dec 2016 | China, Gusu District | ||
aptX | $20M | 28 Jan 2016 | Belfast, Northern Ireland, United Kingdom | ||
Ascentage Pharma | $15M | 14 Aug 2015 | Jiangsu |
